Clinical Trial Update: Oxaliplatin and Cetuximab in First-line Treatment of Metastatic Colorectal Cancer (mCRC) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating oxaliplatin plus cetuximab as first-line therapy for metastatic colorectal cancer; the study is completed with results posted in 2011.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• ERBITUX (cetuximab)
• Eloxatin (oxaliplatin)

Snippet

Sponsor: Merck KGaA, Darmstadt, Germany | Conditions: Neoplasm Metastasis, Colorectal Cancer | Phase 2 | Status: COMPLETED | Results posted: 2011-10-04